USPTO Examiner BOATENG AFUA BAMFOAA - Art Unit 1617

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18976941Method and Composition for an Improved Bioavailability Delivery SystemDecember 2024August 2025Allow811YesNo
17993693ULTRASOUND-TRIGGERED NANOCARRIERSNovember 2022June 2025Abandon3130NoNo
17908521PHARMACEUTICAL COMPOSITIONS OF A KINASE INHIBITORAugust 2022January 2026Abandon4010NoNo
17636138OPHTHALMIC PHARMACEUTICAL COMPOSITION, PREPARATION METHODS AND USES OF THE SAMEJuly 2022February 2026Allow4811YesNo
17792834MEDICINAL COMPOSITIONS FOR CARBON DIOXIDE BASED METERED DOSE INHALERSJuly 2022August 2025Abandon3710NoNo
17841672LIPID NANOPARTICLE COMPOSITIONS AND METHODS AS CARRIERS OF CANNABINOIDS IN STANDARDIZED PRECISION-METERED DOSAGE FORMSJune 2022February 2026Abandon4420NoNo
17779702MUPS TABLET COMPRISING RIBOFLAVINMay 2022April 2025Abandon3510NoNo
17776481NANOPARTICLES FOR MEDICAL AND DIAGNOSITC APPLICATIONSMay 2022November 2025Allow4220YesNo
17741462ANTIMICROBIAL NANO-SURFACTANT AND METHODSMay 2022February 2026Allow4601YesNo
17765386SOY PROTEINS FOR PREPARATION OF GELS, FIBERS AND FILMSMarch 2022March 2026Allow4711YesNo
17762175Polymeric micelle, methods of production and uses thereofMarch 2022September 2025Abandon4201NoNo
17689380PACKAGING SOLUTIONSMarch 2022December 2025Allow4521YesNo
17637374A METHOD FOR OBTAINING ION-EXCHANGE POLYMERIC HYDROGELS FOR EYE TREATMENT AND HYDROGEL LENSES THEREOFFebruary 2022June 2025Abandon4001NoNo
17651670PEGLOTICASE FOR TREATMENT OF GOUT IN RENAL TRANSPLANT RECIPIENTSFebruary 2022April 2025Abandon3810NoNo
17635667Contoured Dressing For Tissue TherapyFebruary 2022November 2025Abandon4520NoNo
17632567HERBICIDAL COMBINATIONFebruary 2022March 2026Allow4940YesYes
17631330COSMETIC COMPOSITION IN THE FORM OF A COMPACT, IMPACT-RESISTANT POWDERJanuary 2022March 2026Allow4911YesNo
17628474COLOURING EFFECT PIGMENTS AND PRODUCTION THEREOFJanuary 2022October 2025Abandon4520NoNo
17625331THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF MITOTIC KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITORJanuary 2022September 2025Abandon4511NoNo
17624151A WATER-IN-OIL EMULSION WITH EMOLLIENT AND METHODS OF USING THE SAMEDecember 2021October 2025Abandon4620YesYes
17623459CITRIC ACID COATED WOUND DRESSING COMPOSITIONS AND METHODS OF MANUFACTUREDecember 2021March 2025Abandon3810NoNo
17622732CROSS-LINKED HYALURONIC ACID HYDROGELS COMPRISING PROTEINSDecember 2021October 2025Abandon4611NoNo
17622001COMPOSITION AND METHODS FOR PARASITE CONTROLDecember 2021October 2025Allow4520YesNo
17621103OIL-IN-WATER EMULSION GEL COMPOSITIONDecember 2021December 2025Allow4830NoNo
17620391NANOPARTICLES COMPRISING QUINONE W METHIDES AND COMPOSITIONS FOR USEDecember 2021February 2025Abandon3801NoNo
17618662DELAYED AND SUSTAINED DELIVERY OF ANTICANCER DRUGSDecember 2021November 2025Abandon4721NoNo
17617785WATER-ACTIVATED MUCOADHESIVE COMPOSITIONS AND METHODS OF DELIVERING BIOLOGICALLY ACTIVE SUBSTANCESDecember 2021March 2026Allow5121YesNo
17614955NANOTUBES IN POROUS PARTICLESNovember 2021March 2026Allow5121YesNo
17612115FUNCTIONALIZED FULLERENE GEL TUMOR TREATMENTNovember 2021August 2025Abandon4520NoNo
17611583LOCAL ANESTHETIC COMPRISING A TRP CHANNEL MODULATORNovember 2021January 2026Abandon5011NoNo
17610965UNIT DOSAGE FORM FOR TRANSMUCOSAL DRUG DELIVERY OF AN ACTIVE PHARMACEUTICAL INGREDIENTNovember 2021December 2025Allow4921YesNo
17610254Improved Lyophilized Formulations Involving Hyaluronic Acid and Plasmatic Proteins, and Uses ThereofNovember 2021March 2025Abandon4001NoNo
17603299SPRAY-DRIED FORMULATION OF A PYRIDAZINONE TRPC5 INHIBITOROctober 2021November 2025Allow4921YesNo
17601262POWDER COSMETIC CONTAINING ULTRAVIOLET WAVELENGTH-CONVERTING SUBSTANCE, AND METHOD FOR PRODUCING SAMEOctober 2021October 2025Abandon4820YesNo
17601317OIL-IN-WATER TYPE EMULSIFICATION COMPOSITION CONTAINING UV WAVELENGTH CONVERSION SUBSTANCEOctober 2021December 2025Allow5030YesNo
17593932COSMETIC USE OF AMYLOSE-RICH STARCH AS FILM-FORMING AGENT WITH BARRIER AND FIXATIVE EFFECTSSeptember 2021May 2025Abandon4420NoNo
17599444OIL-IN-WATER EMULSION COSMETICSeptember 2021July 2025Abandon4620NoNo
17598344MULTICOMPONENT THERMOPLASTIC PRODUCTSeptember 2021December 2025Abandon5020NoYes
17442523SLEEP AID TRANSDERMAL PATCH AND ITS PROCESS OF PREPARATIONSeptember 2021January 2025Abandon4010NoNo
17441404IMPLANT WITH INTRINSIC ANTIMICROBIAL EFFICACY, AND METHOD FOR THE PRODUCTION THEREOFSeptember 2021December 2024Abandon3910NoNo
17440605NON-AQUEOUS DISPERSION, PREPARATION METHOD THEREFOR, AND COSMETIC COMPOSITION COMPRISING SAMESeptember 2021March 2026Allow5430YesNo
17440017MEDICAL DEVICE AND PROCESS OF PREPARING A MEDICAL DEVICESeptember 2021November 2024Abandon3810NoNo
17439938COATING-SECURING AGENTSeptember 2021November 2025Allow5030YesNo
17439353COMPOSITE MICROCAPSULESSeptember 2021May 2025Allow4420NoNo
17472954METHOD FOR TREATING CANCER WITH KIDNEY PROTECTIONSeptember 2021December 2025Abandon5130NoNo
17437998CELL ENCAPSULATION DEVICES AND METHODS OF USING SAMESeptember 2021October 2024Abandon3710NoNo
17472173COMPOSITION, LIPID PARTICLE MANUFACTURING KIT, SUBSTANCE DELIVERY METHOD, AND DETECTION METHODSeptember 2021November 2025Allow5021YesNo
17412388MICRONEEDLE ARRAY AND METHOD OF PRODUCING MICRONEEDLE ARRAYAugust 2021May 2025Abandon4520NoNo
17433039PARTICULATE AMORPHOUS MESOPOROUS MAGNESIUM CARBONATE MATERIALAugust 2021May 2025Allow4520YesNo
17310689SUSTAINED-RELEASE LIPID PREFORMULATION AND PHARMACEUTICAL COMPOSITION FOR SUSTAINED-RELEASE INJECTION IN FORM OF LIPID SOLUTION CONTAINING SAMEAugust 2021January 2025Allow4120NoNo
17430021Materials and Methods for Enhanced Treatment and Prevention of BiofilmsAugust 2021November 2025Abandon5121NoNo
17422574AGRICULTURAL CHEMICAL PREPARATION CONTAINING DIFENOCONAZOLE, AND METHOD FOR STABILIZING SAID AGRICULTURAL CHEMICAL PREPARATIONJuly 2021August 2025Allow4930NoNo
17309943A LIQUID AGRICULTURAL ADJUVANTJuly 2021February 2026Allow5530YesNo
17417320METHOD OF CONTROLLING WEEDSJune 2021January 2025Abandon4310NoNo
17413910MICROEMULSION COMPOSITIONS OF TOPRAMEZONEJune 2021March 2025Abandon4520NoNo
17413933HERBICIDE COMPOSITION AND APPLICATION THEREOFJune 2021September 2024Abandon4001NoNo
17296878A HERBAL MEDICINE COMPOSITION FOR TREATMENT OF DENGUE AND THEIR PRODUCTIONMay 2021August 2024Abandon3901NoNo
17288184ABSORBABLE IMPLANTABLE DEVICEApril 2021August 2025Allow5220NoNo
17276866Microbicide Ammonium-Imidazolium Oligomers and Their Anti-Fungal CompositionsMarch 2021September 2024Abandon4201NoNo
17266227IMPLANTABLE BIOMATERIAL, AND METHOD OF MANUFACTURING THEREOFFebruary 2021November 2025Allow5720YesNo
17053131METHODS OF APPLYING ONE OR MORE CERTAIN HETEROARYL-1,2,4-TRIAZOLE AND HETEROARYL-TETRAZOLE COMPOUNDS TO CONTROL DAMAGE ON PLANTS, PROPAGATION MATERIAL THEREOF, AND PLANT DERIVED PRODUCTSNovember 2020July 2024Abandon4501NoNo
16982366PEST REPELLENT COMPOSITIONSeptember 2020July 2024Abandon4610NoNo
17015266HERBICIDE FORMULATION CONTAINING GLUFOSINATE, SOLID HERBICIDE FORMULATION CONTAINING GLYPHOSATE, AND, USE OF HERBICIDE FORMULATIONSeptember 2020June 2025Abandon5730NoNo
16718226USE OF AN EXTRACT OF PART OF A ROCKET PLANT FOR STIMULATING THE DEFENSES OF PLANTS AND TREES AND ASSOCIATED COMPOSITION AND METHODDecember 2019September 2025Allow6062NoNo
16493783ANTIMICROBIAL POLYMER COATING COMPOSITION AND ANTIMICROBIAL POLYMER FILMSeptember 2019March 2026Allow6091YesNo
16518310LOW VOLATILITY HERBICIDAL COMPOSITIONSJuly 2019March 2025Allow6091YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BOATENG, AFUA BAMFOAA.

Strategic Value of Filing an Appeal

Total Appeal Filings
2
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
2
(100.0%)
Filing Benefit Percentile
0.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner BOATENG, AFUA BAMFOAA - Prosecution Strategy Guide

Executive Summary

Examiner BOATENG, AFUA BAMFOAA works in Art Unit 1617 and has examined 47 patent applications in our dataset. With an allowance rate of 42.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.

Allowance Patterns

Examiner BOATENG, AFUA BAMFOAA's allowance rate of 42.6% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BOATENG, AFUA BAMFOAA receive 2.11 office actions before reaching final disposition. This places the examiner in the 56% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BOATENG, AFUA BAMFOAA is 46 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +68.1% benefit to allowance rate for applications examined by BOATENG, AFUA BAMFOAA. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 34.6% of applications are subsequently allowed. This success rate is in the 77% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 11.1% of cases where such amendments are filed. This entry rate is in the 11% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Petition Practice

When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.